The DOI matches its Crossref record.
Reversible and Covalent Binding of Drugs to Human Serum Albumin: Methodological Approaches and Physiological Relevance
Abstract
Human serum albumin (HSA) plays a fundamental role in the transport of drugs, metabolites, and endogenous ligands. Binding to HSA controls the free, active concentration of a drug, provides a reservoir for a long duration of action, and ultimately affects drug absorption, metabolism, distribution and excretion. The free concentration of a drug can also be affected by interaction with co-administered drugs or by pathological conditions that can modify to a significant extent the binding properties of the carrier, resulting in important clinical impacts for drugs that have a relatively narrow therapeutic index. This manuscript will review the physiological role of albumin in the human body and the pharmacological consequences of drug-albumin binding, and then focus on the structure and the properties of the protein binding sites, as studied by different methodologies. Among these, biochromatography on immobilized albumin has been shown to be a rapid and effective tool for the characterization of albumin binding sites and their enantioselectivity, and for the study of the changes in the binding properties of the protein arising by interaction between different ligands. We will discuss the potential offered by the combined use of circular dichroism on the same protein/drug system in solution, not only for the determination of binding parameters and the detection of displacement phenomena, but also for the identification of conformational features underlying binding stereoselectivity. In particular, the essential role of these methodologies in the study of the enantioselective phenomena occurring in the HSA binding of chiral drugs will be addressed. The effect of reversible or covalent binding of drugs will also be discussed and examples of physiological relevance reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Human serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
Signaling Mechanisms Regulating Endothelial Permeability
Mehta, D., & Malik, A. B. (2006) · Physiological Reviews · doi:10.1152/physrev.00012.2005 · Cited by 1,720
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
The extraordinary ligand binding properties of human serum albumin
Fasano, M., Curry, S., Terreno, E., Galliano, M., Fanali, G., Narciso, P., Notari, S., & Ascenzi, P. (2005) · IUBMB Life (International Union of Biochemistry and Molecular Biology: Life) · doi:10.1080/15216540500404093 · Cited by 1,086
Albumin: Biochemical properties and therapeutic potential†
Quinlan, G. J., Martin, G. S., & Evans, T. W. (2005) · Hepatology · doi:10.1002/hep.20720 · Cited by 984
Albumin-based drug delivery: harnessing nature to cure disease
Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 683
Protein-Based Nanoparticles as Drug Delivery Systems
Hong, S., Choi, D. W., Kim, H. N., Park, C. G., Lee, W., & Park, H. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070604 · Cited by 619
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Spada, A., Emami, J., Tuszynski, J. A., & Lavasanifar, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00046 · Cited by 591
Huang, S., Strong, J. M., Zhang, L., Reynolds, K. S., Nallani, S., Temple, R., Abraham, S., Habet, S. A., Baweja, R. K., Burckart, G. J., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312153 · Cited by 396
Interactive Association of Drugs Binding to Human Serum Albumin
Yang, F., Zhang, Y., & Liang, H. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033580 · Cited by 376
“Therefore, HSA not only protects the bound drugs against oxidation and influences the in vivo drug distribution, but also alters the pharmacokinetic and pharmacodynamic properties of drugs [7,10–13].”
BackgroundClinical impact of serum proteins on drug delivery
Kratz, F., & Elsadek, B. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.028 · Cited by 375
Tang, J., Luan, F., & Chen, X. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.034 · Cited by 366
Oettl, K., & Stauber, R. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707251 · Cited by 357
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
Schmidt, S., Gonzalez, D., & Derendorf, H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21916 · Cited by 335
Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Kälebo, P., Muelhofer, E., Misselwitz, F., Eriksson, B. I., & Mueck, W. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-12-0714 · Cited by 273
Drug interactions evaluation: An integrated part of risk assessment of therapeutics
Zhang, L., Reynolds, K. S., Zhao, P., & Huang, S.-M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.016 · Cited by 125
“For example, interactions may result from altered drug distribution involving specific plasma binding proteins (Bertucci and Domenici, 2002) or changed CYP enzyme systems at the transcriptional or post-translational levels by cytokines and cytokine modulators (Aitken et al.”
BackgroundShamsi, A., Mohammad, T., Anwar, S., Alajmi, M. F., Hussain, A., Hassan, M. I., Ahmad, F., & Islam, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.01.134 · Cited by 73
Metadata
- Authors
- Bertucci, C., & Domenici, E.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2002-08-01
- Volume
- 9
- Issue
- 15
- Pages
- 1463-1481
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2328379097
- Cited by
- 354
- References
- 0
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.